BLOG

endpoints

Tessera unveils promising in vivo gene editing treatment for sickle cell in an increasingly competitive field: #ASGCT24

Tessera Therapeutics, a well-funded startup based outside of Boston, announced Friday that it developed a lipid nanoparticle that shuttles a gene editing therapy directly to the bone marrow of mice.